Glycemic Variability in Pancreatogenic Diabetes Mellitus: characteristics, Risks, Potential Mechanisms, and Treatment Possibilities.

Yuyan Sun, Bing Lu, Yuanwen Hu, Yingqi Lv, Shao Zhong
Author Information
  1. Yuyan Sun: Department of Endocrinology, Gusu School, Nanjing Medical University, The First People's Hospital of Kunshan, Kunshan, 215300, People's Republic of China.
  2. Bing Lu: Department of Endocrinology, Gusu School, Nanjing Medical University, The First People's Hospital of Kunshan, Kunshan, 215300, People's Republic of China.
  3. Yuanwen Hu: Department of Gastroenterology, The First People's Hospital of Kunshan, Kunshan, 215300, People's Republic of China.
  4. Yingqi Lv: Division of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, People's Republic of China.
  5. Shao Zhong: Department of Endocrinology, Gusu School, Nanjing Medical University, The First People's Hospital of Kunshan, Kunshan, 215300, People's Republic of China. ORCID

Abstract

In recent years, pancreatogenic diabetes mellitus has garnered significant attention due to its high incidence, complications, and mortality rates. Glycemic variability (GV) can increase the risk of pancreatogenic diabetes mellitus and its associated complications; however, the precise mechanism remains unclear. The effective control of GV is crucial for preventing the onset of pancreatic diabetes mellitus and improving prognosis. Both diet and antidiabetic medications have substantial effects on GV. However, many patients are prescribed suboptimal or even harmful drugs. Therefore, to provide a comprehensive treatment basis for clinicians to prevent and treat pancreatogenic diabetes mellitus, this study aimed to elucidate the relationship between GV and pancreatogenic diabetes mellitus; investigate the potential mechanisms (such as oxidative stress, inflammatory response, insulin resistance, and lipid metabolism disorders); provide lifestyle guidance; and recommend drug selections to reduce the GV in patients with pancreatogenic diabetes mellitus.

Keywords

References

  1. Nutrients. 2022 Sep 01;14(17): [PMID: 36079874]
  2. J Diabetes Res. 2020 Nov 24;2020:6666403 [PMID: 33299890]
  3. Cytokine. 2022 Feb;150:155768 [PMID: 34823207]
  4. JAMA. 2021 Jun 8;325(22):2273-2284 [PMID: 34077502]
  5. Diabetes Care. 2019 Sep;42(9):1675-1683 [PMID: 31227582]
  6. Pancreas. 2021 Nov-Dec 01;50(10):1376-1381 [PMID: 35041336]
  7. JAMA. 2021 Jun 8;325(22):2262-2272 [PMID: 34077499]
  8. Nat Commun. 2017 May 03;8:14803 [PMID: 28466852]
  9. J Diabetes Sci Technol. 2021 Jan;15(1):134-140 [PMID: 31282179]
  10. Diabetes Care. 2020 Sep;43(9):2106-2112 [PMID: 32616613]
  11. Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31 [PMID: 31862745]
  12. Diabetes Technol Ther. 2020 Apr;22(4):256-264 [PMID: 31638433]
  13. Diabetes Care. 2020 Feb;43(2):389-397 [PMID: 31843948]
  14. Diabetes Obes Metab. 2013 Jun;15(6):503-12 [PMID: 23121289]
  15. Diabetes Care. 2018 Feb;41(2):258-266 [PMID: 29246950]
  16. Clin Gastroenterol Hepatol. 2014 Feb;12(2):219-28 [PMID: 23856359]
  17. Lancet Gastroenterol Hepatol. 2016 Nov;1(3):226-237 [PMID: 28404095]
  18. Diabetes Obes Metab. 2020 Apr;22(4):699-704 [PMID: 31750601]
  19. PLoS One. 2016 Nov 8;11(11):e0165923 [PMID: 27824898]
  20. Pancreatology. 2016 Sep-Oct;16(5):748-55 [PMID: 27401909]
  21. Clin Pharmacol Ther. 2020 Mar;107(3):580-587 [PMID: 31553055]
  22. J Gastrointest Surg. 2016 Nov;20(11):1844-1853 [PMID: 27619808]
  23. Lancet Gastroenterol Hepatol. 2021 Aug;6(8):668-675 [PMID: 34089654]
  24. Diabetes Care. 2022 May 1;45(5):1141-1150 [PMID: 35226735]
  25. Signal Transduct Target Ther. 2024 Feb 28;9(1):38 [PMID: 38413567]
  26. Front Endocrinol (Lausanne). 2024 Jan 19;14:1285147 [PMID: 38313835]
  27. Antioxid Redox Signal. 2017 Apr 1;26(10):501-518 [PMID: 27225690]
  28. Pancreas. 2013 Nov;42(8):1227-37 [PMID: 24152948]
  29. Clin Transl Gastroenterol. 2020 Nov;11(11):e00251 [PMID: 33259158]
  30. Cells. 2022 Aug 08;11(15): [PMID: 35954309]
  31. Diabetes Technol Ther. 2022 Sep;24(9):611-618 [PMID: 35604792]
  32. N Engl J Med. 2022 Oct 20;387(16):1477-1487 [PMID: 36198143]
  33. Pancreas. 2014 Nov;43(8):1291-8 [PMID: 25036911]
  34. Heart Fail Rev. 2022 May;27(3):951-960 [PMID: 33620621]
  35. Diabetes Care. 2021 Jan;44(Suppl 1):S221-S222 [PMID: 33298427]
  36. J Diabetes Sci Technol. 2024 Jul;18(4):956-967 [PMID: 36576014]
  37. Crit Care. 2010;14(4):R130 [PMID: 20615210]
  38. Drugs. 2023 Aug;83(12):1077-1090 [PMID: 37410209]
  39. J Gastroenterol. 2020 Aug;55(8):775-788 [PMID: 32494905]
  40. Curr Opin Gastroenterol. 2020 Sep;36(5):443-451 [PMID: 32618612]
  41. Diabetes. 2004 Apr;53(4):955-62 [PMID: 15047610]
  42. ACS Omega. 2022 May 31;7(23):19764-19774 [PMID: 35722005]
  43. Endocrinol Metab (Seoul). 2017 Jun;32(2):241-247 [PMID: 28685513]
  44. Expert Rev Clin Pharmacol. 2020 Apr;13(4):461-468 [PMID: 32129106]
  45. Diabet Med. 2022 Aug;39(8):e14882 [PMID: 35569007]
  46. Nutr Metab Cardiovasc Dis. 2015 Oct;25(10):898-905 [PMID: 26232910]
  47. Diabetes Care. 2017 Jun;40(6):736-741 [PMID: 28389582]
  48. Pancreas. 2017 Oct;46(9):1188-1195 [PMID: 28902790]
  49. Surgery. 2019 Aug;166(2):184-192 [PMID: 30979427]
  50. Crit Care. 2010;14(6):327 [PMID: 21067560]
  51. Int J Environ Res Public Health. 2021 Mar 18;18(6): [PMID: 33803558]
  52. Diabetes Metab J. 2021 May;45(3):339-348 [PMID: 32602273]
  53. Diabetes Care. 2021 Sep;44(9):2045-2052 [PMID: 34362812]
  54. Endocrine. 2020 Jun;68(3):518-525 [PMID: 32103407]
  55. Endocr J. 2020 Apr 28;67(4):455-468 [PMID: 31996492]
  56. Pancreas. 2019 May/Jun;48(5):670-681 [PMID: 31091214]
  57. Diabetes Care. 2013 Dec;36(12):4091-7 [PMID: 24170754]
  58. Endocrine. 2010 Feb;37(1):201-8 [PMID: 20963571]
  59. Front Pharmacol. 2023 Jul 11;14:1193610 [PMID: 37497113]
  60. Cardiovasc Diabetol. 2021 Jan 7;20(1):9 [PMID: 33413392]
  61. Nutrients. 2021 Jul 28;13(8): [PMID: 34444750]
  62. United European Gastroenterol J. 2017 Mar;5(2):153-199 [PMID: 28344786]
  63. Sci Rep. 2021 Mar 1;11(1):4875 [PMID: 33649395]
  64. Gastroenterology. 2011 Jul;141(1):150-6 [PMID: 21334333]
  65. J ASEAN Fed Endocr Soc. 2021;36(2):167-171 [PMID: 34966201]
  66. Am J Gastroenterol. 2023 Jan 1;118(1):26-40 [PMID: 36148840]
  67. J Mol Biol. 2020 Mar 6;432(5):1461-1493 [PMID: 31634466]
  68. Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):175-184 [PMID: 30482911]
  69. Diabetes Care. 2021 Jun;44(6):1368-1376 [PMID: 33879536]
  70. United European Gastroenterol J. 2022 Mar;10(2):179-189 [PMID: 35188346]
  71. Arch Physiol Biochem. 2018 Dec;124(5):401-409 [PMID: 29235373]
  72. Mayo Clin Proc. 2017 May;92(5):762-773 [PMID: 28302323]
  73. Diabetes Metab Syndr. 2017 Nov;11 Suppl 1:S233-S241 [PMID: 28065464]
  74. Endocr Pract. 2015 Apr;21 Suppl 1:1-87 [PMID: 25869408]
  75. Diabetes Care. 2017 Jul;40(7):e92-e93 [PMID: 28637892]
  76. Diabetes Res Clin Pract. 2014 Feb;103(2):256-68 [PMID: 23481145]
  77. Diabetes Care. 2020 Jan;43(1):37-43 [PMID: 31530663]
  78. Expert Opin Investig Drugs. 2021 Jul;30(7):737-747 [PMID: 33993813]
  79. Eur J Endocrinol. 2021 Apr;184(4):R151-R163 [PMID: 33460395]
  80. Front Endocrinol (Lausanne). 2022 May 26;13:890090 [PMID: 35721710]
  81. World J Diabetes. 2020 Jul 15;11(7):280-292 [PMID: 32843931]
  82. Eur J Endocrinol. 2021 Apr;184(4):R137-R149 [PMID: 33460393]
  83. Front Endocrinol (Lausanne). 2020 Sep 23;11:644 [PMID: 33071962]
  84. Diabetes Technol Ther. 2021 Mar;23(S1):S35-S39 [PMID: 33470882]
  85. Zhonghua Nei Ke Za Zhi. 2023 Feb 1;62(2):212-216 [PMID: 36740415]
  86. J Diabetes Investig. 2019 May;10(3):714-722 [PMID: 30171747]
  87. Diabetes Res Clin Pract. 2020 Mar;161:108032 [PMID: 32006646]
  88. touchREV Endocrinol. 2023 Jul;19(2):16-21 [PMID: 38046184]
  89. Diabetes Metab Syndr. 2021 Mar-Apr;15(2):627-636 [PMID: 33743360]
  90. Pancreatology. 2021 Oct;21(7):1237-1246 [PMID: 34332908]

Word Cloud

Created with Highcharts 10.0.0diabetespancreatogenicmellitusGVcomplicationsGlycemicvariabilitypatientsprovidedrugrecentyearsgarneredsignificantattentionduehighincidencemortalityratescanincreaseriskassociatedhoweverprecisemechanismremainsuncleareffectivecontrolcrucialpreventingonsetpancreaticimprovingprognosisdietantidiabeticmedicationssubstantialeffectsHowevermanyprescribedsuboptimalevenharmfuldrugsThereforecomprehensivetreatmentbasisclinicianspreventtreatstudyaimedelucidaterelationshipinvestigatepotentialmechanismsoxidativestressinflammatoryresponseinsulinresistancelipidmetabolismdisorderslifestyleguidancerecommendselectionsreduceVariabilityPancreatogenicDiabetesMellitus:characteristicsRisksPotentialMechanismsTreatmentPossibilitiesantihyperglycemicglucosefluctuationglycemictherapy

Similar Articles

Cited By

No available data.